Tirzepatide vs. semaglutide: the honest side-by-side.

Dual GIP/GLP-1 vs single GLP-1. 22.5% at 72 weeks vs 14.9%. Head-to-head SURPASS-2 says one. Cardiovascular outcomes SELECT says the other. Here’s the comparison clinicians actually want.

Comparison9 min read

Key takeaway

Tirzepatide (Mounjaro / Zepbound) hits two receptors and produced 22.5% mean body-weight reduction at 72 weeks in SURMOUNT-1. Semaglutide (Ozempic / Wegovy) hits one receptor and produced 14.9% mean body-weight reduction at 68 weeks in STEP-1. Head-to-head in SURPASS-2, tirzepatide won every endpoint. But semaglutide has the SELECT cardiovascular outcomes trial showing a 20% reduction in heart attacks, strokes, and CV death. Tirzepatide’s equivalent (SURPASS-CVOT) is pending.

At a glance

Article typeComparison
Main guideTirzepatide: complete guide
Regulatory statusFDA-approved“Tirzepatide is the first FDA-approved dual agonist” (Tirzepatide: complete guide)
ClassMetabolic & weight
Body systemsEndocrine & metabolism
Studies cited6 in this article · 10 across 15 articles on Tirzepatide
ProductTirzepatide product page

The tirzepatide vs semaglutide comparison is one of the more consequential in recent metabolic pharmacology: one head-to-head trial favors tirzepatide; a separate, larger cardiovascular outcomes trial favors semaglutide. This article walks through the head-to-head data, the cardiovascular evidence, and the specific dimensions on which each compound prevailed.

Both are FDA-approved and in active clinical use as of 2026. Neither emerges as a clear winner across all dimensions. They differ in specific ways that matter for specific clinical priorities — mechanism, magnitude, cardiovascular evidence, tolerability, and pricing each tell a somewhat different story.

Figure 1

SURPASS-2 head-to-head: tirzepatide vs semaglutide body-weight reduction

Mean body-weight reduction in kilograms at 40 weeks across 1,879 adults with type 2 diabetes randomized to tirzepatide 5/10/15 mg or semaglutide 1 mg. All three tirzepatide doses produced greater body-weight reduction than semaglutide 1 mg in this head-to-head design.

0 kg 3 kg 6 kg 9 kg 12 kg 5.7 kg Semaglutide 1 mg 7.6 kg Tirzepatide 5 mg 9.3 kg Tirzepatide 10 mg 11.2 kg Tirzepatide 15 mg Mean body-weight reduction (kg)

Source: Frias et al, NEJM 2021 (SURPASS-2 head-to-head trial in T2D).

Quick comparison table

Table 1

Tirzepatide vs. Semaglutide, attribute by attribute

Attribute Tirzepatide Semaglutide
Receptor profile Dual agonist: GIP, GLP-1 Single agonist: GLP-1
Molecular scaffold 39 aa linear peptide, C20 fatty-diacid acyl chain 31 aa linear peptide, C18 fatty-diacid acyl chain
Administration route (clinical) Once-weekly subcutaneous injection (approved formulations) Once-weekly subcutaneous injection; oral tablet formulation also approved (Rybelsus)
Peak Phase III body-weight reduction (obesity) 22.5% at 72 weeks (SURMOUNT-1, 15 mg) 14.9% at 68 weeks (STEP-1, 2.4 mg)
≥15% threshold response 71% (SURMOUNT-1, 15 mg) 50.5% (STEP-1, 2.4 mg)
≥20% threshold response 57% (SURMOUNT-1, 15 mg) 32% (STEP-1, 2.4 mg)
Head-to-head data (T2D) SURPASS-2: outperformed semaglutide at all three doses Outperformed on every comparison
GI adverse-event rate ~60–80% at highest dose ~60–80% at highest dose
Cardiovascular outcomes (gold-standard) SURPASS-CVOT ongoing; SURMOUNT-MMO ongoing SELECT: 20% reduction in MACE in established CVD
FDA approval status Mounjaro (T2D, 2022), Zepbound (obesity, 2023) Ozempic (T2D, 2017), Wegovy (obesity, 2021), Rybelsus (oral T2D, 2019)
Cash-pay US list price ~$1,060/month (Zepbound) ~$1,350/month (Wegovy)
Maintenance / discontinuation SURMOUNT-4: 14% regain on switch to placebo STEP-4: 6.9% regain on switch to placebo

Mechanism: one receptor vs two

Semaglutide acts at one receptor. Tirzepatide acts at two. That mechanistic difference underlies the magnitude gap observed in the Phase III trials.

What semaglutide does

Semaglutide is a GLP-1 receptor agonist. GLP-1 is an incretin gut hormone that stimulates glucose-dependent insulin secretion and signals satiety to the central nervous system.

GLP-1 receptor activation produces glucose-dependent insulin release, glucagon suppression at meals, slowed gastric emptying, and reduced food intake through central satiety pathways — effects replicated consistently across the Phase III trial program.

Approved formulations include Wegovy (obesity indication), Ozempic (type 2 diabetes), and Rybelsus (oral type 2 diabetes).

What tirzepatide adds

Tirzepatide adds a second receptor: GIP (glucose-dependent insulinotropic polypeptide), the other major incretin hormone. In healthy physiology, GIP accounts for approximately two-thirds of incretin activity; GLP-1 accounts for the remainder. In type 2 diabetes the GIP response is blunted, which led to early skepticism about GIP-targeting agents.

Subsequent research revised that view. GIP receptor co-activation in obesity contexts has been reported to augment satiety beyond GLP-1 alone, improve adipose nutrient handling, and potentially attenuate GLP-1-associated nausea.

The dual-agonism hypothesis — that co-activating both receptors would produce greater weight reduction than GLP-1 agonism alone — was evaluated at scale in the 2022 SURMOUNT-1 trial, which reported 22.5% mean body-weight reduction at 72 weeks for tirzepatide 15 mg. In STEP-1, semaglutide 2.4 mg produced 14.9% mean body-weight reduction at 68 weeks.

That’s a cross-trial number, not a head-to-head. Different populations, different protocols. The cleaner comparison is SURPASS-2.

Tirzepatide

Dual agonist GIP / GLP-1 39 aa

The same compound cited across the SURMOUNT and SURPASS trials in this comparison. Lab-verified identity and purity.

View Tirzepatide

SURPASS-2: the head-to-head that matters

SURPASS-2 is the most-cited head-to-head evidence for this comparison. Frías and colleagues enrolled 1,879 adults with type 2 diabetes inadequately controlled on metformin. Study participants were randomized to tirzepatide 5, 10, or 15 mg weekly, or semaglutide 1 mg weekly, over 40 weeks.

Key reported outcomes:

  • HbA1c (blood sugar marker) reduction: −2.01% (tirzepatide 5 mg), −2.24% (10 mg), −2.30% (15 mg) vs −1.86% (semaglutide). All three tirzepatide doses beat semaglutide.
  • Body-weight change at 40 weeks: −7.6 kg (tirzepatide 5 mg), −9.3 kg (10 mg), −11.2 kg (15 mg) vs −5.7 kg (semaglutide). All three tirzepatide doses beat semaglutide.
  • HbA1c <5.7% (non-diabetic range) at 40 weeks: 27% / 40% / 46% (tirzepatide) vs 19% (semaglutide).
  • Dropout rate from side effects: roughly the same across all four arms (5–7%).

SURPASS-2 is the cleanest available comparison. Tirzepatide won every glycemic and body-weight endpoint.

One caveat. The trial used semaglutide 1 mg, not the higher 2.4 mg obesity dose. That’s appropriate for a T2D trial (1 mg was the highest T2D dose at the time), but it’s not semaglutide running at its top obesity setting.

“

Tirzepatide was non-inferior and superior to semaglutide, with respect to the mean change in glycated hemoglobin level from baseline to 40 weeks. The estimated treatment differences with tirzepatide as compared with semaglutide ranged from −0.15 percentage points for the 5-mg dose to −0.45 percentage points for the 15-mg dose.

— Frías et al., New England Journal of Medicine, 2021 (SURPASS-2)

SELECT: the trial that flips the comparison

If SURPASS-2 is tirzepatide’s trial, SELECT is semaglutide’s. Lincoff and colleagues enrolled 17,604 adults, 45 or older, with established cardiovascular disease and overweight or obesity. No diabetes. Randomized to semaglutide 2.4 mg weekly or placebo. Mean follow-up: 39.8 months.

The primary endpoint was MACE (major adverse cardiovascular events) — cardiovascular death, nonfatal heart attack, or nonfatal stroke. Reported outcomes:

  • MACE rate: 6.5% with semaglutide vs 8.0% with placebo (HR 0.80; 95% CI 0.72–0.90; P<0.001). A 20% relative risk reduction.
  • Cardiovascular and all-cause mortality: reductions consistent with the MACE finding.
  • Mean body-weight reduction: 9.4% — lower than STEP-1’s 14.9% because SELECT enrolled a different population (older, sicker, lower adherence).

SELECT is among the most consequential cardiovascular outcomes trials in obesity pharmacotherapy. The trial demonstrated that semaglutide reduced MACE events in study participants with established CVD and overweight/obesity. A 20% relative MACE reduction is a magnitude comparable to that reported for statins in primary prevention cohorts.

Tirzepatide doesn’t have a SELECT-equivalent published yet. SURPASS-CVOT (T2D) and SURMOUNT-MMO (obesity) are both ongoing as of 2026. The mechanistic prediction is that tirzepatide will show CV benefit too. But until the trial reads out, it’s “plausible,” not “proven.”

Tolerability: basically a tie

Both compounds produce the same GI side effects. Nausea, vomiting, diarrhea, constipation. They’re dose-related, mostly mild to moderate, mostly during the dose-escalation period, and they fade with continued use.

Any-GI-event rates run 60–80% in the Phase III trials for both compounds. Dropouts from side effects sit in the 4–7% range for both.

The honest read: there is no clear winner on tolerability. Individual variation within each compound exceeds the average gap between them. Clinical literature notes that titration response in a given study participant is more predictive of tolerability than between-compound averages.

Maintenance: evidence from discontinuation studies

Both compounds have been evaluated in discontinuation studies. The evidence indicates that pharmacological effect is tied to continued treatment — consistent with the biology of chronic conditions addressed by these agents.

STEP-4 enrolled semaglutide research subjects through 20 weeks of treatment, then randomized continuers versus placebo-switchers for an additional 48 weeks. Continuers lost an additional 7.9% body weight; placebo-switchers regained 6.9%.

SURMOUNT-4 applied the same design to tirzepatide. Continuers lost further weight; placebo-switchers regained 14.0%.

The weight regain observed on treatment withdrawal reflects the chronic nature of the underlying condition rather than a direct drug effect. Clinical literature has noted this has implications for long-term treatment planning, adherence, and cost-benefit analysis over multi-year horizons.

Evidence gaps. Both compounds produced substantial weight regain on discontinuation in controlled trials (~14% for tirzepatide, ~7% for semaglutide). Neither has decade-long real-world follow-up data. Trial populations were younger and healthier than the broader populations receiving these agents in routine care. The cardiovascular safety signal is favorable based on available data, but the very-long-term safety record is still accumulating.

Pricing and access

Both approved formulations carry four-figure monthly list prices in the US. Zepbound (tirzepatide, obesity indication) has been priced at roughly $1,060/month; Wegovy (semaglutide, obesity indication) at roughly $1,350/month.

The approximately 25% list-price gap between the two is frequently moderated by insurance coverage, which is the dominant cost variable for most research subjects and clinical participants. Medicare coverage for obesity indications has been limited but is evolving; employer benefit plans vary in their formulary coverage of both agents.

Researchers sourcing reference-grade tirzepatide or semaglutide for in vitro or preclinical in vivo studies should obtain material from a research-grade supplier with documented identity verification, purity testing, and lot-specific Certificates of Analysis — not from clinical prescription channels.

Tirzepatide

20 mg ≥99% pure Lyophilized

39-aa dual GIP/GLP-1 agonist with C20 fatty-diacid acyl chain. The same reference compound used across the cited SURMOUNT trials. COA available with each lot.

Learn more

Which compound prevails on which dimension?

The evidence base does not produce a single winner. The answer depends on the endpoint being prioritized. A summary by dimension:

  • Weight reduction magnitude: tirzepatide demonstrated larger mean reductions in both the SURMOUNT-1 single-arm data and the SURPASS-2 head-to-head.
  • Cardiovascular outcomes (established CVD): semaglutide has published proof-of-concept via SELECT — a 20% MACE reduction in research subjects with obesity and prior cardiovascular disease. Tirzepatide’s equivalent cardiovascular outcomes trial (SURPASS-CVOT) has not yet reported.
  • Tolerability: GI adverse-event rates were comparable across Phase III programs for both agents. Individual response variation within each compound appears to exceed mean between-compound differences.
  • Oral administration: semaglutide is the only compound in this class with an approved oral formulation (Rybelsus). Tirzepatide is available only in subcutaneous injection form.
  • Glycemic endpoints in type 2 diabetes: SURPASS-2 reported that tirzepatide outperformed semaglutide on HbA1c reduction at all three tested doses. Both are current first-line agents for T2D.

Clinical literature as of 2026 characterizes the choice between these agents as less about a single “better compound” and more about alignment with individual clinical priorities, existing comorbidities, and treatment context — a decision appropriately made in consultation with prescribing clinicians on a per-subject basis.

What to know now

  • Mechanism: tirzepatide is a dual GIP/GLP-1 agonist. Semaglutide is a GLP-1 receptor agonist only.
  • Phase III weight reduction: 22.5% mean at 72 weeks (tirzepatide 15 mg, SURMOUNT-1) vs 14.9% mean at 68 weeks (semaglutide 2.4 mg, STEP-1).
  • Head-to-head: SURPASS-2 (T2D, 40 weeks) — tirzepatide outperformed semaglutide 1 mg on every glycemic and weight endpoint.
  • Cardiovascular outcomes: SELECT demonstrated a 20% MACE reduction with semaglutide in study participants with established CVD. Tirzepatide’s equivalent trials (SURPASS-CVOT, SURMOUNT-MMO) remain ongoing as of 2026.
  • Discontinuation studies: weight regain was observed on treatment withdrawal in both programs (~14% tirzepatide in SURMOUNT-4; ~7% semaglutide in STEP-4).
  • Approved formulation pricing (US list): Zepbound ~$1,060/month; Wegovy ~$1,350/month.
  • Tolerability: GI adverse-event rates were comparable across both Phase III programs; individual response variation within each compound exceeded mean between-compound differences.

What we’re watching

Four things over the next 24 months. First, SURPASS-CVOT readout for tirzepatide in T2D. That’s the SELECT-equivalent trial that closes the main gap in tirzepatide’s evidence base. Second, SURMOUNT-MMO readout for tirzepatide in obesity-without-diabetes. The equivalent SELECT population. Third, additional semaglutide indications. Kidney outcomes. Heart failure outcomes. The GLP-1 class keeps expanding. Fourth, the next-generation compounds. Retatrutide (triple agonist). CagriSema (amylin + GLP-1). Oral incretins. They’ll reshape this comparison again.

Also in the library

More for endocrine & metabolism

All 38 compounds for endocrine & metabolism

Sources: Jastreboff 2022, New England Journal of Medicine; Wilding 2021, New England Journal of Medicine; Fr&iacute;as 2021, New England Journal of Medicine; Lincoff 2023, New England Journal of Medicine; Aronne 2024, JAMA; Melson 2024, International Journal of Obesity. All 6 citations

Back to the research library

References

  1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
  2. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
  3. Frías, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519
  4. Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., et al. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine, 389(24), 2221–2232. https://doi.org/10.1056/NEJMoa2307563
  5. Aronne, L. J., Sattar, N., Horn, D. B., et al. (2024). Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: The SURMOUNT-4 randomized clinical trial. JAMA, 331(1), 38–48. https://doi.org/10.1001/jama.2023.24945
  6. Melson, E., Ashraf, U., Papamargaritis, D., & Davies, M. J. (2024). What is the pipeline for future medications for obesity? International Journal of Obesity, 49(3), 433–451. https://doi.org/10.1038/s41366-024-01473-y